The MMWR series of publications is published by the
Epidemiology Program Office, Centers for Disease
Control and Prevention (CDC), U.S. Department of
Health and Human Services, Atlanta, GA 30333.

SUGGESTED CITATION
Centers for Disease Control and Prevention. Sexually
transmitted diseases treatment guidelines 2002.





Diseases Characterized
by Vaginal Discharge
Management of Patients Who Have
Vaginal Infections
Vaginal infection is usually characterized by a vaginal discharge or vulvar itching and irritation; a vaginal odor may be present. The three diseases most frequently associated with vaginal discharge are trichomoniasis (caused by T. vaginalis), bacterial vaginosis (caused by a replacement of the normal vaginal flora by an overgrowth of anaerobic microorganisms,
mycoplasmas, and Gardnerella vaginalis), and candidiasis (usually caused by Candida albicans). MPC caused by C. trachomatis or N. gonorrhoeae can sometimes cause vaginal discharge. Although vulvovaginal candidiasis and bacterial vaginosis are not usually transmitted sexually, they are included in this section because these infections are often diagnosed in women
being evaluated for STDs. The cause of vaginal infection can be diagnosed by pH and microscopic examination of the discharge. The pH of the vaginal
secretions can be determined by narrow-range pH paper for the elevated pH (>4.5) typical of BV or trichomoniasis. Discharge can be examined by diluting one sample in one to two drops of 0.9% normal saline solution on one slide and a second sample in 10% potassium hydroxide (KOH) solution.
An amine odor detected before or immediately after applying KOH suggests BV. A cover slip is placed on the slides, and they are examined under a microscope at low- and high-dry power. The motile T. vaginalis or the clue cells of BV usually are identified easily in the saline specimen. The yeast or pseudohyphae of Candida species are more easily identified in the KOH specimen. However, their absence does not preclude candidal or trichomonal infection, because several studies have demonstrated the presence of these pathogens by using polymerase chain reaction (PCR) after a negative microscopic exam. The presence of objective signs of external vulvar inflammation in the absence of vaginal pathogens, along with a minimal amount of discharge, suggests the possibility of mechanical, chemical, allergic, or other noninfectious irritation of the vulva. Culture for T. vaginalis is more sensitive than microscopic examination. Laboratory testing fails to identify the cause of vaginitis among a minority of women.
Bacterial Vaginosis BV is a clinical syndrome resulting from replacement of the normal H2O2-producing Lactobacillus sp. in the vagina with high concentrations of anaerobic bacteria (e.g., Prevotella sp. and Mobiluncus sp.), G. vaginalis, and Mycoplasma hominis. BV is the most prevalent cause of vaginal discharge or malodor; however, up to 50% of women with BV may not report symptoms of BV. The cause of the microbial alteration is not
fully understood. BV is associated with having multiple sex partners, douching, and lack of vaginal lactobacilli; it is unclear whether BV results from acquisition of a sexually transmitted pathogen. Women who have never been sexually active are rarely affected. Treatment of the male sex partner has not been beneficial in preventing the recurrence of BV.
Diagnostic Considerations BV can be diagnosed by the use of clinical or Gram-stain criteria. Clinical criteria require three of the following symptoms or signs:
• a homogeneous, white, noninflammatory discharge that smoothly coats the vaginal walls;
• the presence of clue cells on microscopic examination;
• a pH of vaginal fluid >4.5; and
• a fishy odor of vaginal discharge before or after addition of 10% KOH (i.e., the whiff test).
When a Gram stain is used, determining the relative concentration of the bacterial morphotypes characteristic of the altered flora of BV is an acceptable laboratory method for diagnosing BV. Culture of G. vaginalis is not recommended as a diagnostic tool because it is not specific. However, a DNA probe based test for high concentrations of G. vaginalis (Affirm™ VP III, manufactured by Becton Dickinson, Sparks, Maryland) may have clinical utility. Cervical Pap tests have limited clinical utility for the diagnosis of BV because of low sensitivity. Other commercially available tests that may be useful for the diagnosis of BV include a card test for the detection of elevated pH and trimethylamine (FemExam® test card, manufactured by Cooper Surgical, Shelton, Connecticut) and prolineaminopeptidase (Pip Activity TestCard™, manufactured by Litmus Concepts, Inc., Santa Clara, California). Treatment The established benefits of therapy for BV in non-pregnant women are to a) relieve vaginal symptoms and signs of infection
and b) reduce the risk for infectious complications after abortion or hysterectomy. Other potential benefits include the reduction of other infectious complications (e.g., HIV and other STDs). All women who have symptomatic disease require treatment.

Vol. 51 / RR-6 Recommendations and Reports 43
BV during pregnancy is associated with adverse pregnancy
outcomes, including premature rupture of the membranes,
preterm labor, preterm birth, and postpartum endometritis.
The established benefit of therapy for BV in pregnant women
is to relieve vaginal symptoms and signs of infection. Additional
potential benefits of therapy include a) reducing the
risk for infectious complications associated with BV during
pregnancy and b) reducing the risk for other infections (e.g.,
other STDs or HIV). The results of several investigations indicate
that treatment of pregnant women who have BV and
who are at high risk for preterm delivery (i.e., those who previously
delivered a premature infant) may reduce the risk for
prematurity (52–54). Therefore, high-risk pregnant women
who have asymptomatic BV may be evaluated for treatment.
The bacterial flora that characterizes BV have been recovered
from the endometria and salpinges of women who have
PID. BV has been associated with endometritis, PID, and vaginal
cuff cellulitis after invasive procedures, including endometrial
biopsy, hysterectomy, hysterosalpingography, placement
of an IUD, cesarean section, and uterine curettage. The
results of two randomized controlled trials indicated that treatment
of BV with metronidazole substantially reduced
postabortion PID (55,56). Three trials that evaluated the use
of anaerobic antimicrobial coverage (metronidazole) for routine
operative prophylaxis before abortion and seven trials that
evaluated this additional coverage for women undergoing hysterectomy
found a substantial reduction (range: 10%–75%)
in post-operative infectious complications (57–66). Because
of the increased risk for postoperative infectious complications
associated with BV, some specialists recommend that
before performing surgical abortion or hysterectomy, providers
screen and treat women with BV in addition to providing
routine prophylaxis. However, more information is needed
before recommending treatment of asymptomatic BV before
other invasive procedures.
Recommended Regimens
Metronidazole 500 mg orally twice a day for 7 days,
OR
Metronidazole gel 0.75%, one full applicator (5 g)
intravaginally, once a day for 5 days,
OR
Clindamycin cream 2%, one full applicator (5 g)
intravaginally at bedtime for 7 days.
NOTE: Patients should be advised to avoid consuming alcohol
during treatment with metronidazole and for 24 hours
thereafter. Clindamycin cream and ovules are oil-based
and might weaken latex condoms and diaphragms. Refer to
condom product labeling for additional information.
The recommended metronidazole regimens are equally efficacious.
The vaginal clindamycin cream appears less efficacious
than the metronidazole regimens. The alternative
regimens have lower efficacy for BV.
Alternative Regimens
Metronidazole 2 g orally in a single dose,
OR
Clindamycin 300 mg orally twice a day for 7 days,
OR
Clindamycin ovules 100 g intravaginally once at
bedtime for 3 days.
One randomized trial evaluating the clinical equivalency of
intravaginal metronidazole gel 0.75% once daily versus twice
daily found similar cure rates 1 month after therapy (67). One
randomized trial that evaluated the equivalency of clindamycin
cream and clindamycin ovules found that cure rates did not
differ significantly (68). Metronidazole 2 g single-dose therapy
is an alternative regimen because of its lower efficacy for
treatment of BV. Although FDA has approved metronidazole
750-mg extended release tablets once daily for 7 days, no data
have been published on the clinical equivalency of this
regimen with other regimens.
Studies are currently underway to evaluate the efficacy of
vaginal lactobacilli suppositories in addition to oral metronidazole
for the treatment of BV. No data support the use of
non-vaginal lactobacilli or douching for the treatment of BV.
Follow-Up
Follow-up visits are unnecessary if symptoms resolve.
Because recurrence of BV is not unusual, women should be
advised to return for additional therapy if symptoms recur.
Another recommended treatment regimen may be used to treat
recurrent disease. No long-term maintenance regimen with
any therapeutic agent is recommended.
Management of Sex Partners
The results of clinical trials indicate that a woman’s response
to therapy and the likelihood of relapse or recurrence are not
affected by treatment of her sex partner(s) (69–71). Therefore,
routine treatment of sex partners is not recommended.
Special Considerations
Allergy or Intolerance to the Recommended
Therapy
Clindamycin cream or oral clindamycin is preferred in case
of allergy or intolerance to metronidazole. Metronidazole gel
can be considered for patients who do not tolerate systemic
metronidazole, but patients allergic to oral metronidazole
should not be administered metronidazole vaginally.
44 MMWR May 10, 2002
Pregnancy
All symptomatic pregnant women should be tested and
treated. BV has been associated with adverse pregnancy
outcomes (e.g., premature rupture of the membranes,
chorioamnionitis, preterm labor, preterm birth, postpartum
endometritis, and post-cesarean wound infection). Some specialists
prefer using systemic therapy to treat possible subclinical
upper genital tract infections among women at low risk for
preterm delivery (i.e., those who have no history of delivering
an infant before term). Existing data do not support the use of
topical agents during pregnancy. Evidence from three trials
suggests an increase in adverse events (e.g., prematurity and
neonatal infections), particularly in newborns, after use
of clindamycin cream (72–74). Multiple studies and
meta-analyses have not demonstrated a consistent association
between metronidazole use during pregnancy and teratogenic
or mutagenic effects in newborns (75–77).
Recommended Regimens
Metronidazole 250 mg orally three times a day for 7 days
OR
Clindamycin 300 mg orally twice a day for 7 days.
Because treatment of BV in asymptomatic pregnant women
at high risk for preterm delivery (i.e., those who have previously
delivered a premature infant) with a recommended regimen
has reduced preterm delivery in three of four randomized
controlled trials (52–54,78), some specialists recommend the
screening and treatment of these women. However, the optimal
treatment regimens have not been established. The screening
(if conducted) and treatment should be performed at the
first prenatal visit.
The two trials that examined the use of metronidazole during
pregnancy used the 250-mg regimen; the recommended
regimen for BV in nonpregnant women is 500 mg twice daily.
Some specialists also recommend this higher dose for treatment
of pregnant women. In one published study, women
with BV were treated at 19 weeks with a regimen of an initial
dose of 2 g, followed by a 2-g dose 2 days later; the regimen
was repeated 4 weeks later (78). This regimen was not
effective in reducing preterm birth in any group of women.
Data are conflicting regarding whether treatment of asymptomatic
pregnant women who are at low risk for preterm
delivery reduces adverse outcomes of pregnancy. Several
unpublished trials have evaluated screening and treatment for
BV among asymptomatic low-risk pregnant women in the first
or early second trimester. One trial, using oral clindamycin,
demonstrated a reduction in spontaneous preterm birth;
another indicated a reduction in postpartum infectious
complications (79).
Follow-Up of Pregnant Women
Treatment of BV in asymptomatic pregnant women who
are at high risk for preterm delivery might prevent adverse
pregnancy outcomes. Therefore, a follow-up evaluation
1 month after completion of treatment should be considered
to evaluate whether therapy was effective.
HIV Infection
Patients who have BV and also are infected with HIV
should receive the same treatment regimen as those who are
HIV-negative.
Trichomoniasis
Trichomoniasis is caused by the protozoan T. vaginalis. Most
men who are infected with T. vaginalis do not have symptoms;
others have NGU. Many infected women have symptoms
characterized by a diffuse, malodorous, yellow-green discharge
with vulvar irritation. However, some women have minimal
or no symptoms. Diagnosis of vaginal trichomoniasis is usually
performed by microscopy of vaginal secretions, but this
method has a sensitivity of only about 60%–70%. Culture is
the most sensitive commercially available method of diagnosis.
No FDA-approved PCR test for T. vaginalis is available in
the United States, but such testing may be available from commercial
laboratories that have developed their own PCR tests.
Recommended Regimen
Metronidazole 2 g orally in a single dose.
Alternative Regimen
Metronidazole 500 mg twice a day for 7 days.
The nitroimidazoles comprise the only class of drugs useful
for the oral or parenteral therapy of trichomoniasis. Of these,
only metronidazole is readily available in the United States
and approved by the FDA for the treatment of trichomoniasis.
In randomized clinical trials, the recommended metronidazole
regimens have resulted in cure rates of approximately
90%–95%; ensuring treatment of sex partners might increase
this rate. Treatment of patients and sex partners results in
relief of symptoms, microbiologic cure, and reduction of transmission.
Metronidazole gel has been approved for treatment
of BV. However, like other topically applied antimicrobials
that are unlikely to achieve therapeutic levels in the urethra or
perivaginal glands, it is considerably less efficacious for treatment
of trichomoniasis (<50%) than oral preparations of metronidazole.
Therefore, metronidazole gel is not recommended
for use. Several other topically applied antimicrobials have
occasionally been used for treatment of trichomoniasis, but it
Vol. 51 / RR-6 Recommendations and Reports 45
is unlikely that these preparations have greater efficacy than
metronidazole gel.
Follow-Up
Follow-up is unnecessary for men and women who become
asymptomatic after treatment or who are initially asymptomatic.
Certain strains of T. vaginalis can have diminished susceptibility
to metronidazole; however, infections caused by
most of these organisms respond to higher doses of metronidazole.
If treatment failure occurs with either regimen, the
patient should be re-treated with metronidazole 500 mg twice
a day for 7 days. If treatment failure occurs again, the patient
should be treated with a single, 2-g dose of metronidazole
once a day for 3–5 days.
Patients with laboratory-documented infection who do not
respond to the 3–5 day treatment regimen and who have not
been reinfected should be managed in consultation with a specialist;
evaluation of such cases should ideally include
determination of the susceptibility of T. vaginalis to metronidazole.
Consultation is available from CDC (tel: 770-488-4115;
website: http://www.cdc.gov/std/).
Management of Sex Partners
Sex partners of patients with T. vaginalis should be treated.
Patients should be instructed to avoid sex until they and their
sex partners are cured (i.e., when therapy has been completed
and patient and partner(s) are asymptomatic [in the absence
of a microbiologic test of cure]).
Special Considerations
Allergy, Intolerance, and Adverse Reactions
Patients with an immediate-type allergy to metronidazole
can be managed by desensitization (80). Topical therapy with
drugs other than nitroimidazoles can be attempted, but cure
rates are low (<50%).
Pregnancy
Vaginal trichomoniasis has been associated with adverse pregnancy
outcomes, particularly premature rupture of the membranes,
preterm delivery, and low birthweight. Data have not
indicated that treating asymptomatic trichomoniasis during
pregnancy lessens that association (81). Women who are symptomatic
with trichomoniasis should be treated to ameliorate
symptoms.
Women may be treated with 2 g of metronidazole in a single
dose. Multiple studies and meta-analyses have not demonstrated
a consistent association between metronidazole use
during pregnancy and teratogenic or mutagenic
effects in infants (75–77).
HIV Infection
Patients who have trichomoniasis and also are infected with
HIV should receive the same treatment regimen as those who
are HIV-negative.
Vulvovaginal Candidiasis
Vulvovaginal candidiasis (VVC) usually is caused by
C. albicans but occasionally is caused by other Candida sp. or
yeasts. Typical symptoms of VVC include pruritus and vaginal
discharge. Other symptoms include vaginal soreness, vulvar
burning, dyspareunia, and external dysuria. None of these
symptoms is specific for VVC. An estimated 75% of women
will have at least one episode of VVC, and 40%–45% will
have two or more episodes. On the basis of clinical presentation,
microbiology, host factors, and response to therapy, VVC
can be classified as either uncomplicated or complicated (Box 2).
Approximately 10%–20% of women will have complicated
VVC, suggesting diagnostic and therapeutic considerations.
Uncomplicated VVC Complicated VVC
• Sporadic or infrequent vulvovaginal candidiasis • Recurrent vulvovaginal candidiasis
OR OR
• Mild-to-moderate vulvovaginal candidiasis • Severe vulvovaginal candidiasis
OR OR
• Likely to be C. albicans • Non-albicans candidiasis
OR OR
• Non-immunocompromised women • Women with uncontrolled diabetes, debilitation,
or immunosuppression or those who are pregnant
Box 2. Classification of vulvovaginal candidiasis (VVC)
46 MMWR May 10, 2002
Uncomplicated VVC
Diagnostic Considerations in Uncomplicated VVC
A diagnosis of Candida vaginitis is suggested clinically by
pruritus and erythema in the vulvovaginal area; a white discharge
may be present. The diagnosis can be made in a woman
who has signs and symptoms of vaginitis when either a) a wet
preparation (saline, 10% KOH) or Gram stain of vaginal discharge
demonstrates yeasts or pseudohyphae or b) a culture or
other test yields a positive result for a yeast species. Candida
vaginitis is associated with a normal vaginal pH (<4.5). Use of
10% KOH in wet preparations improves the visualization of
yeast and mycelia by disrupting cellular material that might
obscure the yeast or pseudohyphae. Identifying Candida by
culture in the absence of symptoms is not an indication for
treatment, because approximately 10%–20% of women harbor
Candida sp. and other yeasts in the vagina. VVC can
occur concomitantly with STDs, and treatment of all pathogens
present is warranted. Most healthy women with uncomplicated
VVC have no precipitating factors. However, in
a minority of women who have asymptomatic Candida
colonization, antibiotic use precipitates VVC.
Treatment
Short-course topical formulations (i.e., single dose and regimens
of 1–3 days) effectively treat uncomplicated VVC. The
topically applied azole drugs are more effective than nystatin.
Treatment with azoles results in relief of symptoms and negative
cultures in 80%–90% of patients who complete therapy.
Recommended Regimens
Intravaginal Agents:
Butoconazole 2% cream 5 g intravaginally for 3 days,***
OR
Butoconazole 2% cream 5 g (Butaconazole1-sustained
release), single intravaginal application,
OR
Clotrimazole 1% cream 5 g intravaginally for 7–14
days,***
OR
Clotrimazole 100 mg vaginal tablet for 7 days,
OR
Clotrimaz Clotrimazole ole 100 mg vaginal tablet, two tablets for
3 days,
OR
Clotrimaz Clotrimazole ole 500 mg vaginal tablet, one tablet in a single
application,
OR
Miconazole 2% cream 5 g intravaginally for 7 days,***
OR
Miconazole 100 mg vaginal suppository, one suppository
for 7 days,***
OR
Miconazole 200 mg vaginal suppository, one suppository
for 3 days,***
OR
Nystatin 100,000-unit vaginal tablet, one tablet for
14 days,
OR
Tioconazole 6.5% ointment 5 g intravaginally in a single
application,***
OR
Terconazole 0.4% cream 5 g intravaginally for 7 days,
OR
Terconazole 0.8% cream 5 g intravaginally for 3 days,
OR
Terconazole 80 mg vaginal suppository, one suppository
for 3 days.
Oral Agent:
Fluconazole 150 mg oral tablet, one tablet in single dose.
NOTE: The creams and suppositories in this regimen are oilbased
and may weaken latex condoms and diaphragms. Refer
to condom product labeling for further information.
Preparations for intravaginal administration of butaconazole,
clotrimazole, miconazole, and tioconazole are available overthe-
counter (OTC). Self-medication with OTC preparations
should be advised only for women who have been diagnosed
previously with VVC and who have a recurrence of the same
symptoms. Any woman whose symptoms persist after using
an OTC preparation or who has a recurrence of symptoms
within 2 months should seek medical care. Unnecessary or
inappropriate use of OTC preparations is common and can
lead to delay of treatment of other etiologies of vulvovaginitis
that could result in adverse clinical outcomes.
Follow-Up
Patients should be instructed to return for follow-up visits
only if symptoms persist or recur within 2 months of onset of
initial symptoms.
Management of Sex Partners
VVC is not usually acquired through sexual intercourse;
treatment of sex partners is not recommended but may be
considered in women who have recurrent infection. A minority
of male sex partners may have balanitis, which is characterized
by erythematous areas on the glans of the penis in ***Over-the-counter (OTC) preparations.
Vol. 51 / RR-6 Recommendations and Reports 47
conjunction with pruritus or irritation. These men benefit from
treatment with topical antifungal agents to relieve symptoms.
Special Considerations
Allergy to or Intolerance of the Recommended Therapy.
Topical agents usually cause no systemic side effects, although
local burning or irritation may occur. Oral agents occasionally
cause nausea, abdominal pain, and headache. Therapy with
the oral azoles has been associated rarely with abnormal elevations
of liver enzymes. Clinically important interactions might
occur when these oral agents are administered with other drugs,
including astemizole, calcium channel antagonists, cisapride,
coumadin, cyclosporin A, oral hypoglycemic agents,
phenytoin, protease inhibitors, tacrolimus, terfenadine,
theophylline, trimetrexate, and rifampin.
Complicated VVC
Recurrent Vulvovaginal Candidiasis
Recurrent VVC (RVVC), usually defined as four or more
episodes of symptomatic VVC each year, affects a small percentage
of women (<5%). The pathogenesis of RVVC is poorly
understood, and most women who have RVVC have no
apparent predisposing or underlying conditions. Vaginal cultures
should be obtained from patients with RVVC to confirm
the clinical diagnosis and to identify unusual species,
including non-albicans species, particularly Candida glabrata
(C. glabrata does not form pseudohyphae or hyphae and is
not easily recognized on microscopy). C. glabrata and other
non-albicans Candidia species are found in 10%–20% of
patients with RVVC. Conventional antimycotic therapies are
not as effective against these species as against C. albicans.
Treatment
Each individual episode of RVVC caused by C. albicans responds
well to short duration oral or topical azole therapy.
However, to maintain clinical and mycologic control, specialists
recommend a longer duration of initial therapy (e.g.,
7–14 days of topical therapy or a 150-mg, oral dose of
fluconazole repeated 3 days later) to achieve mycologic
remission before initiating a maintenance antifungal regimen.
Maintenance Regimens
Maintenance antifungals are selected on the basis of pharmacologic
characteristics of individual agents and route of
administration. Recommended regimens include clotrimazole
(500-mg dose vaginal suppositories once weekly), ketoconazole
(100-mg dose once daily), fluconazole (100–150-mg dose once
weekly), and itraconazole (400-mg dose once monthly or
100-mg dose once daily). Although all maintenance regimens
should be continued for 6 months, an estimated one in
10,000–15,000 persons exposed to ketoconazole may develop
hepatotoxicity. Patients receiving long-term ketoconazole
should be monitored for toxicity.
Suppressive maintenance antifungal therapies are effective
in reducing RVVC. However, 30%–40% of women will have
recurrent disease once maintenance therapy is discontinued.
Routine treatment of sex partners is controversial. Although
C. albicans azole resistance is rare in vaginal isolates, surveillance
of recurrent isolates for development of resistance is
prudent.
Severe VVC
Severe vulvovaginitis (i.e., extensive vulvar erythema, edema,
excoriation, and fissure formation) has lower clinical response
rates in patients treated with short courses of topical or oral
therapy. Either 7–14 days of topical azole or 150 mg of
fluconazole in two sequential doses (second dose 72 hours
after initial dose) is recommended.
Non-albicans VVC
The optimal treatment of non-albicans VVC remains
unknown. Longer duration of therapy (7–14 days) with a nonfluconazole
azole drug is recommended as first-line therapy. If
recurrence occurs, 600 mg of boric acid in a gelatin capsule is
recommended, administered vaginally once daily for 2 weeks.
This regimen has clinical and mycologic eradication rates of
approximately 70%. Additional options include topical 4%
flucytosine; however, referral to a specialist is advised. Safety
data regarding the long-term use of these regimens are lacking.
If non-albicans VVC continues to recur, a maintenance
regimen of 100,000 units of nystatin delivered daily via
vaginal suppositories has been successful.
Compromised Host
Women with underlying debilitating medical conditions
(e.g., those with uncontrolled diabetes or those receiving corticosteroid
treatment) do not respond as well to short-term
therapies. Efforts to correct modifiable conditions should be
made, and more prolonged (i.e., 7–14 days) conventional
antimycotic treatment is necessary.
Pregnancy
VVC often occurs during pregnancy. Only topical azole
therapies, applied for 7 days, are recommended for use among
pregnant women.







Centers for Disease Control and Prevention
David W. Fleming, M.D.
Acting Director
Julie L. Gerberding, M.D.
Acting Deputy Director for Science and Public Health
Dixie E. Snider, Jr., M.D., M.P.H.
Associate Director for Science
Epidemiology Program Office
Stephen B. Thacker, M.D., M.Sc.
Director
Office of Scientific and Health Communications
John W. Ward, M.D.
Director
Editor, MMWR Series
Suzanne M. Hewitt, M.P.A.
Managing Editor
Rachel J. Wilson
Project Editor
Malbea A. Heilman
Beverly J. Holland
Visual Information Specialists
Michele D. Renshaw
Erica R. Shaver
Information Technology Specialis

questa pagina è aggiornata al 10/05/2005